Meeting
2023 ASCO Annual Meeting
Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.
Authors
Paul Kent
FibroFighters Foundation, River Forest, IL
Paul Kent , Jordan C Tasse , Erik Schadde , Tom Kato , Abhinav Humar , Oliver M Fisher , Matthew Dixon , Tom Stockwell , Albert Cornelius , Thomas Kim , Jessica Ellison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4076)
DOI
10.1200/JCO.2023.41.16_suppl.4076
Abstract #
4076
Poster Bd #
397
Abstract Disclosures
Similar Posters
First Author: Paul Kent
Poster
2019 Gastrointestinal Cancers Symposium
Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.
First Author: Sakti Chakrabarti
Poster
2022 ASCO Annual Meeting
Gemcitabine-docetaxel in patients with relapsed high-grade osteosarcoma after first-line treatment with high-dose ifosfamide: A retrospective multicenter study.
First Author: Maria Grazia Pionelli
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ryan Sugarman